Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

NCT07244874 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

TNBC - Triple-Negative Breast Cancer
PD-L1 Positive

Interventions

DRUG: Sacituzumab tirumotecan
DRUG: Toripalimab

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

[object Object]